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Abstract
BACKGROUND:
Breast cancer is the most common type of cancer in women despite advances in research
and detection methods. Approximately 25 to 30 percent of newly diagnosed cases of breast
cancer will overexpress HER2, human epidermal growth factor receptor 2, and are at a greater
risk for disease progression and poorer clinical outcomes. The traditional treatment is associated
with irreversible cardiac dysfunction. An alternative treatment involving lapatinib plus
capecitabine has been reported in some randomized controlled clinical trials comparing treatment
outcomes. To quantify the effectiveness of lapatinib plus capecitabine combination therapy
versus capecitabine monotherapy in treating metastatic breast cancer, a systemic review seems
necessary. In this thesis, meta-analysis was performed to synthesize the ratio of the odds of
patient death or disease progression for breast cancer patients who are treated with a combination
therapy to the odds for patients who are treated with monotherapy.
METHODS:
Several randomized clinical trials are identified comparing combination therapy lapatinib
plus capecitabine versus capecitabine monotherapy in women with metastatic HER2 positive
breast cancer that had disease progression after treatment with regimens that included an
anthracycline, a taxane, and trastuzumab. Patients in the treatment arm received lapatinib dosed
at 1,500 mg per day continuously plus capecitabine 2,000 mg per square meter of body surface
area on days 1 through 14 of a 21 day cycle. Patients in the control arm received capecitabine at
a dose of 2,500 mg per square meter of body surface area on days 1 through 14 of a 21 day cycle.
Mantel–Haenszel fixed effect meta-analysis was used to combine the data to evaluate frequency
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of the events between combination therapy and monotherapy treatments in a heavily pre-treated
metastatic breast cancer population.
CONCLUSION:
Three eligible clinical trials were identified, reporting outcomes on 1,131 women.
Mantel–Haenszel fixed effect analysis showed the event occurred 26.7 percent less frequently for
women treated with combination lapatinib plus capecitabine (odds ratio [OR], 0.733; 95 percent
confidence interval [CI], 0.565 to 0.952) than patients treated with capecitabine monotherapy.
The use of lapatinib plus capecitabine should be evaluated in clinical trial for newly diagnosed
HER2 positive patients or older patients who might otherwise be exposed to potential serious
adverse side effects as a result of the current first line treatment or patients that have a preexisting heart condition.
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Chapter I: INTRODUCTION
Breast cancer is the most common type of cancer in women despite advances in research and
detection methods. Breast cancer is the second most common cancer in the world, and by far the
most frequent cancer among women with an estimated 1.67 million newly diagnosed cases in
2012 resulting in over 400,000 deaths worldwide (World Health Organization, 2015). Public
health data suggests that the global burden of breast cancer in women, measured by incidence
and mortality, is substantial and on the rise. There is an increasing number of global health
initiatives to address breast cancer including efforts by Susan G. Komen for the Cure ©, the
Breast Health Global Initiative, the U.S. Centers for Disease Control and Prevention, the
American Cancer Society, the National Cancer Institute, and ongoing work by leading oncology
societies in different parts of the world.
In the United States an estimated 234,190 (2,350 men and 231,840 women) will be
diagnosed with breast cancer; and, an estimated 40,730 (440 men and 40,290 women) will die
from breast cancer in 2014 (Jemal, Siegel, Xu &Ward 2014). Approximately 25 to 30 percent of
newly diagnosed cases of breast cancer will overexpress HER2, human epidermal growth factor
receptor 2, and are at greater risk for disease progression and poorer clinical outcomes (Geyer et
al. 2008; Cameron et al. 2010). The HER proteins are transmembrane receptors which regulate:
cell growth, survival, adhesion, migration, and differentiation (Hudis, 2007). In some breast
cancers, HER2 is over-expressed and causes breast cells to reproduce uncontrollably.
In 1998, the FDA approved: doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab as
first-line treatment for women with HER2 positive breast cancer. This first line treatment for
naïve HER2 positive breast cancer showed biological activity in controlling breast cancer
growth. The chemotherapy regimen is abbreviated as ACTH followed by H maintenance for 1
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year. The A refers to Adriamycin® ( doxorubicin, Ben Venue Laboratories, Inc., Bedford, OH),
the C refers to Cytoxan® (cyclophosphamide, Bristol-Myers Squibb, New York, NY), the T
refers to Taxol® (paclitaxel, Bristol-Myers Squibb, New York, NY), and H refers to Herceptin®
(trastuzumab, Genetech, San Francisco, CA).
Unfortunately, this treatment regime is associated with irreversible cardiac dysfunction
which can develop into congestive heart failure (CHF) that can manifest at any time during
treatment and may also occur years and possibly decades after treatment has completed (Bowles
et al., 2012). A retrospective study of 12,000 women who received breast cancer treatment
between 1999 and 2007 reported that patients who received chemotherapy agents such as:
anthracyclines and trastuzumab have a 20 percent increased risk of developing congestive heart
failure within five years after finishing chemotherapy (Bowles et al. 2012; Pinder, Duan,
Goodwin, Hortobagyi & Giordano, 2007). Nevertheless, the side effect profiles of the
chemotherapy agents, especially when used in combination, must be factored into treatment
decision to maximize quality of life and prolonging patient survival. This is of particular
importance to breast cancer survivors because the development of congestive heart failure is
more pronounced in older patients and females.
Patients that have disease progression or reoccurrence following treatment with:
anthracycline, a taxane, and trastuzumab have limited treatment options available due to a lack of
other HER2 antagonists. The data is pooled from HER2 positve metastatic or advanced breast
cancer clinical trials of combination therapy of lapatinib plus capecitabine versus capecitabine
monotherapy. In this thesis, meta-analysis was performed to synthesize the ratio of the odds of
patient death or disease progression for breast cancer patients who are treated with a combination
therapy to the odds for patients who are treated with monotherapy.
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Chapter II: LITERTURE REVIEW

The scientific advancement in treatment of breast cancer is as varied as the history of breast
cancer. In understanding the significant side effects that chemotherapy drug(s) pose to the
patient, one is required to comprehend the significance of the treatment options available to
women who have been diagnosed with breast cancer.
History of Breast Cancer
The history of breast cancer is unique. This type of cancer can be seen by the naked eye as a
result of the transformation of the breast structure. The treatment option for women diagnosed
with breast cancer begins with a journey through the history of medicine.
The ancient Greek physician Hippocrates, the founder of Western Medicine, in 460 B.C.
reported the earliest documented case of breast cancer. He noted that women developed hard
lumps in their breast tissue which would swell and turn black. Hippocrates theorized that the
women suffered from a humoral disease, a systemic imbalance of the humors (blood, phlegm,
yellow and black bile) resulting in illness and death (Random History, 2008).
A major advancement of medicine occurred in the late 1700s when Dr. Henri Le Dran
proposed that breast cancer was a single-site disease which surgery alone could cure (Random
History, 2008). Since the patient was not anesthetized, the need for quickness, and not surgical
skill, left women with horrible disfigurements of the chest wall. The women endured chronic
pain and swelling in the arms from impaired lymphatic circulation (Random History, 2008).
The introduction of anesthesia in the mid-1800s allowed surgeons to have more time to
skillfully remove the breast tissue. The radical mastectomy was introduced by Dr. William
Halstead. A radical mastectomy, more commonly called, a bilateral radical mastectomy in
modern terms, is the complete removal of: both breasts, both pectoral chest muscles (major and
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minor) and the axillary lymph nodes in a single surgical procedure (Donegan & Spratt, 2002).
The radical mastectomy was gold standard in the treatment of breast cancer for 100 years until
the development of chemotherapeutic agents in the mid-1900s (Random History, 2008).
Unfortunately, women still endured chronic pain and swelling following the surgery.
In 1955, Dr. George Crile argued that breast cancer was a systemic disease and argued
against the radical mastectomy indicating the procedure as too invasive and unnecessary. He
proposed a more conservative mastectomy that only removed the breast cancer and some of the
surrounding tissue but not the entire breast. The hormone estrogen receptor was also identified
during this time period and became a useful tool in classifying breast cancer.
The introduction of radiotherapy, hormone therapy, and chemotherapy in the 1970s improved
the survival chance of some women; however, a large majority of women still died from the
disease (Donegan & Spratt, 2002). In 1980s, researchers identified a receptor that was overexpressed in some breast cancer; the HER2 receptor. This was recognized as a cancer
distinguisher, useful in staging and categorizing various breast cancers. The correlation between
the estrogen receptor and HER2 status was not fully understood until the development of
chemotherapy drugs and hormone antagonists which could block or inhibit the specific receptors.
The current knowledge of HER2 positive and estrogen receptor status is what medical
oncologists and researchers are using to develop new chemotherapy treatments in the search of a
cure for breast cancer.
A journey through the history of breast cancer has shown that as medical knowledge has
increased; the treatments and surgical options available to women have advanced; the survival
outcome of this deadly disease has improved. The national awareness which breast cancer has
received in the past two decades has increased funding, both privately and nationally, in hopes of
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finding a cure. The efforts by organizations like Susan G. Komen for the Cure © and
highlighting October as National Breast Cancer Awareness Month has taken breast cancer out of
the closet and into the living rooms of the American household. The treatment options available
for women in the twenty-first century are a vast improvement than what was offered in
Hippocrates’ time.
Chemotherapeutic Agents
A discussion of the drugs utilized and the significant side effects is needed to comprehend
the potential risks women accept when starting chemotherapy treatment. The following drugs
are commonly used in the first line treatment for metastatic breast cancer Adriamycin®
(doxorubicin, Ben Venue Laboratories, Inc., Bedford, OH), Cytoxan® (cyclophosphamide,
Bristol-Myers Squibb, New York, NY), Taxol® (paclitaxel, Bristol-Myers Squibb, New York,
NY), Herceptin® (trastuzumab, Genetech, San Francisco, CA), lapatinib (Tykerb® or Tyverb®,
GlaxoSmithKline, Research Triangle Park, NC), and capecitabine (Xeloda ®, Roche, San
Francisco, CA).
Doxorubicin mode of action is to impede the DNA topoisomerase which repairs damaged
DNA and generating free radical that cause damage to the cell membrane, DNA, and proteins.
Doxorubicin is associated with irreversible cardiac dysfunction. Cardiac dysfunction is defined
as any alteration in the normal function of the heart. Cardiac dysfunction can occur at any dose
of doxorubicin which can manifest as the potentially fatal congestive heart failure (CHF)
occurring at any time during therapy, even months to years after termination of treatment
(Adriamycin [package insert]. Bedford, OH: Ben Venue Laboratories, Inc.; 2006).
Cyclophosphamide and paclitaxel are two chemotherapy agents are not associated with life
threating side effects, but they are still cytotoxic agents. Cyclophosphamide crosslinks DNA
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strands by the addition of an alkyl group of guanine which inhibits DNA replication leading to
cellular apoptosis. Paclitaxel stabilizes the microtubules preventing disassembly during cell
division stopping the cell life cycle. Cyclophosphamide and paclitaxel are associated with
myelosuppression (also known as bone marrow suppression). Myelosuppression is a condition
in which bone marrow activity is decreased resulting in fewer red blood cells, white blood cells,
and platelets. Prolonged myelosuppression can result in bacterial, fungal, or viral infections that
can delay treatment. Myelosuppression is dose related and normally resolves upon a dose
reduction or termination of treatment.
Trastuzumab is a human monoclonal antibody which targets the extracellular domain of the
HER2 receptor that inhibits the phosphorylation of key proteins needed to regulate the cell life
cycle. The breast cancer cells that have been treated with trastuzumab induce immune cells to
kill the cancer cell. The antibody-dependent cell cytotoxicity is an important mechanism in
killing the cancer cells (Hudis, 2007). Trastuzumab was a pivotal advancement in the treatment
of breast cancer. In 2001, research showed that trastuzumab can increase the incidence of
cardiac dysfunction when used in combination with doxorubicin, cyclophosphamide, and
paclitaxel which was an unexpected complication based on preclinical trials (Slamon et al.,
2001). Unfortunately, trastuzumab is associated with a natural and acquired resistance which
can develop during the course of treatment and recurrences following trastuzumab therapy still
occur.
Lapatinib is the first orally available dual inhibitor of both the HER2 and EGFR (epidermal
growth factor receptor) tyrosine kinases; a dual inhibitor may benefit more patients due to the
role of EGFR and HER2 in the progression of various cancers including, but not limited to,
breast, colon, head and neck, and bladder cancers (Kopper, 2008). Lapatinib blocks the
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intracellular domain of the HER2 and EGFR receptors which prevents phosphorylation of key
proteins that regulate the cell life cycle, resulting in mechanisms that lead to cell death. The role
of the EGFR and HER2 in cellular proliferation, differentiation and survival provides strong
rationale for utilizing chemotherapy agents, such as lapatinib, that block EFGR or HER2
signaling pathways in tumors that overexpress EFGR or HER2 (Tevaarwerk & Kolesar, 2009).
Lapatinib is associated with hepatotoxicity and left ventricle ejection fraction (LVEF) decline
that may be severe and result in death (Tykerb® or Tyverb® [package insert], GlaxoSmithKline,
Research Triangle Park, NC, 2015).
Capecitabine is an orally available chemotherapeutic agent used in the treatment of
metastatic breast and colorectal cancers. Capecitabine is a prodrug that is enzymatically
converted into 5-fluorouracil (5FU) by thymidine phosphorlase which is present at a higher
concentration within tumor cells (Walko & Lindley, 2005). The higher concentration of 5FU
inhibits deoxyribonucleic acid (DNA) synthesis in cancer cells thus sparing healthy tissue. The
primary side effect of capecitabine is hand-foot syndrome. Hand-foot syndrome is a thickening
of the skin on the hand and feet that cause severe pain, numbness and/or peeling of the skin.
This reversible side effect is dose dependent and will resolve upon a dose reduction of
capecitabine or discontinuation of treatment.
Clinical Trials
The women who have developed irreversible cardiac dysfunction or have progressive disease
after trastuzumab therapy had few treatment options available until the FDA approved lapatinib
in 2007. The FDA approved lapatinib in combination with capecitabine for the treatment of
HER2 positive breast cancer for those patients who had disease progression while on or after
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trastuzumab therapy. The treatment regimen of lapatinib and capecitabine shows clinical benefit
in the treatment of locally advanced (Stage III) or metastatic (Stage IV) breast cancer.
The combination treatment of lapatinib and capecitabine showed a 51% increase in the time
to tumor progression (TTP), as elaborated by Geyer et al (2006) in the New England Journal of
Medicine. The research also demonstrated no increase of serious side effects or decrease in the
left ventricle ejection fraction (LVEF). However, this study was biased on the population
selection; the eligibility criteria required that the women have normal cardiac function before
starting investigational treatment.
The EGF100151 study by Cameron et al. (2010) showed a need for further research to
determine which patients may have a survival benefit with the addition of lapatinib to
chemotherapy treatments. The TTP was increased in this study which implies that lapatinib and
capecitabine are clinically beneficial to women who have failed trastuzumab therapy. This study
also showed no increase in cardiac toxicity in the treatment arm.
Kaufman, Stein, Casey and Newstat (2008) suggest although breast cancer is currently
incurable, by utilizing the new treatment therapies and strategies, it may allow breast cancer to
be managed as a chronic disease. The research demonstrated a longer TTP then the capecitabine
monotherapy. This study also analyzed the benefit of lapatinib and capecitabine in treating brain
metastasis since both drugs cross the blood-brain barrier. Trastuzumab, however, does not.
Lapatinib plus capecitabine fills a void after the patient had disease progression while on
trastuzumab.
Mantel-Haenszel Meta-Analysis Method
Meta-analysis, the methodologies of synthesizing existing evidence to answer a clinical or
other research question, is a dynamic area of research. The furor of methodological activity
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reflects the clinical importance of meta-analysis and its potential to provide conclusive answers,
rather than incremental knowledge contributions. When the original data is unavailable,
researchers have to combine the evidence in a two stage process, retrieving the relevant summary
effects statistics from publications and using a suitable meta-analysis model to calculate an
overall effect estimate.
The Mantel-Haenszel (MH) meta-analysis method which can be used to calculate odds ratio
(OR), risk ratio (RR), and risk difference (RD) (Mantel & Haenszel, 1959). The MH method is
based on either a fixed effect or random effect model, where the weight is assigned to each study
based on that study alone. Under the fixed effect model, there is an assumption that only one
true effect exists which underlies all the studies in the meta-analysis. However, the random
effects model incorporates an assumption that the different studies are estimating different, yet
related, intervention effects. In both models, the observed effect size in a study is assumed to
estimate the corresponding population effect with random error that stems only from the chance
factor associated with subject level sampling error in that study from the population of potential
subjects. When comparing randomized control trials the goal is to detect incidence of a single
health outcome between different study groups (Borenstein, Hedges, Higgins, & Rothstein,
2009).
Heterogeneity
Heterogeneity refers to the various responses to a given treatment among included studies. It
can relate to the biological differences among individuals, but also to other differences that are
not as easily detectable (Leandro, 2008). Heterogeneity has two sources of variability that
explain the differences in a set of studies utilized in a meta-analysis. One source of variability is
due to sampling error. Sampling error variability is always present in a meta-analysis, because
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every study uses different study patients and no two patients are identical. The other source of
heterogeneity is the between-study variability, which can appear in a meta-analysis when there is
true heterogeneity among population effect size estimated by the individual studies. The
between-studies variability is due to the influence of an indeterminate number of characteristics
that vary among the studies.
Publication Bias
The one type of publication bias that occur in meta-analysis is sampling bias where only
studies showing significant difference are published, this implies that some complete studies are
not published and the results resides in the investigator’s "file drawer" a term coined by
psychologist Robert Rosenthal in 1979. Non -publication is not a direct result of a rejected
manuscript, but a failure of the investigator to write up and submit the trial results (Rosenthal,
1979). Since published studies are easier to identify and retrieve than unpublished studies, or
studies that resulted in negative or null findings; the studies used in a meta-analysis may overrepresent published work and exaggerate statistical significance
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Chapter III: STUDY DESIGN AND METHODS
The studies enrolled randomized patients to receive lapatinib plus capecitabine or
capecitabine monotherapy within strata defined according to disease stage and the presence or
absence of visceral disease (metastatic disease) to other organs such as: bones, liver, lung, and/or
brain. The eligibility criteria for enrollment was documented HER2 positive status by
immunohistochemistry or gene amplification by fluorescence in situ hybridization, locally
advanced or metastatic breast cancer, and minimum prior treatment(s) that included an
anthracycline, a taxane, and trastuzumab.
Trial Identification
I performed a computerized search of MEDLINE database (last search, October 26, 2014),
online proceedings of the San Antonio Breast Cancer Symposium (years 2008-2014; last
searched October 26, 2014), and the online proceeding of the American Society of Clinical
Oncology (ASCO) Annual Meeting (years 2005-2014; last search October 26, 2014), using the
combinations of the following keywords: “breast cancer”, “lapatinib”, “capecitabine”, “HER2”,
“neoplasm” and “chemotherapy.” I reviewed the reference list of every published clinical article
used in the meta-analysis to find any missing relevant studies.
The extractor used the trial eligibility schema (figure 1) to determine which clinical trials met
the research conditions. The following information was recorded about each eligible clinical
trial used in the meta-analysis: first author, journal name and year of publication, number of
patients assign to each treatment arm, the number of outcome events recorded, and the dosing
schedule for both treatment arms.
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Potentially relevant published
articles identified (n= 86)

Reports of nonclinical trials
excluded (n= 63)
 Review papers
 Not studies on humans

Clinical trials screened on basis
of title or abstract (n= 23)

Exclude because non randomized
controlled trials (n= 17)
 Single treatment arm

Randomized controlled trials
reviewed in detail (n= 6)

Randomized, controlled trials
excluded (n= 3)
 Duplicate reports of
previous trials
 Novel capecitabine dosing
Eligible randomized clinical
trials (n=3)

Figure 1
Trial identification schema
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Study Treatment Protocol
Patients in the treatment arm received lapatinib dosed at 1,500 mg per day continuously plus
capecitabine 2,000 mg per square meter of body surface area on days 1 through 14 of a 21 day
cycle. Patients in the control arm received capecitabine at a dose of 2,500 mg per square meter
of body surface area on days 1 through 14 of a 21 day cycle. Baseline characteristics of the
women enrolled in the clinical trials is listed in table 1.
Table 1
Baseline Characteristics of Women Included in the Analysis
Lapatinib + Capecitabine
Cameron
Geyer
Kaufman
Gender
(female/male)

207 / 0

206 / 0

Cancer Stage
IIIB / IIIC

8

7

IV

199

156

Median TTP

18.8 months

Observation
Duration

180 – 220
weeks

163 / 0

Cameron

Capecitabine
Geyer

Kaufman

201 / 0

193 / 0

161 / 0

8

4

96 %
metastatistic

193

154

96 %
metastatistic

8.4 months

6.2 months

16.2 months

4.4 months

4.3 months

70 – 80 weeks

80 – 90 weeks

180 – 220
weeks

70 – 80 weeks

80 – 90 weeks

The study patients were all female for the clinical trials. The Cameron and Geyer studies
reflect a balanced participant number of stage III patients in each arm, but in the Kaufman study
reports 96 percent of the participants had stage IV cancer with no additional information
provided. Stage IIIB or IIIC locally advanced breast cancer means that the patient does not have
a tumor is distant organ such as: bone, brain, liver, or lung. Stage IV is commonly defined as
metastatic breast cancer and it has all the characteristics of Stage III with the inclusion of a tumor
found in one or more of the distant organs listed above.
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Median time to tumor progression (TTP) reflects the length of time from start of treatment
until 50 percent of the women experience death or disease progression the termination criteria for
treatment. Study observation duration is estimated based on the Kaplan-Meier curve. The
baseline characteristics were used to check the data integrity, since the numbers reported in the
journal articles are very similar. The additional information provided by table 1 provides enough
evidence that the clinical trials are unique and data reported is accurate
Mantel-Haenszel Method
When the studies have a dichotomous (binary) data the results of each study can be presented
in a 2×2 table (Table 2) giving the number of participants who experience the event or do not
experience the event (non-event) in each of the two study groups treatment or control.
Table 2
Mantel-Haenszel Data Layout
Study

Event

Treatment

Ai

Control

Ci

NonEvent
Bi

Total
Treated
N1i

Di

N2i

The Mantel-Haenszel (MH) odds ratio is an alternative way of comparing how likely events
are between two groups. The odds ratio is simply the odds of the event occurring in one group
divided by the odds of the event occurring in the other group. I will use ORi to denote the odds
ratio (effect size) for each ith study.
MH Raw Odds Ratio Formula

ORi  ( Ai / Bi )
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(Ci / Di )

Re-arrange above formula to this.

Ai * Di
ORi 
Bi * Ci
MH Variance Formula

ni
Vi 
Bi * Ci

, where ni  Ai  Bi  Ci  Di

The weighted mean ORMH is the sum of the products (effect size ORi times weight Wi)
divided by the sum of the weights. The study weights are assigned with the goal of minimizing
the with-in study error; meaning that larger studies, which have smaller standard errors, are given
more weight than smaller studies, which have larger standard errors.
MH Weight Equation

1
Wi 
Vi
MH Pooled Summary Odds Ratio Equation
k

ORMH 

W (OR)
i

i 1

i

k

W
i 1

i

To determine the strength of this relationship, we can estimate the raw odds ratio across
the 2 x 2 table. Although, the raw odds ratio indicates how much or worse, on average, the
treatment group performed relative to the control group, its scale is asymmetric with a lower
bound of zero and an upper bound of infinity figure 2 (Petscher & Schatschneider, 2013). Thus,
23

the comparison of the OR from each clinical trial is not feasible since they can have different
scales.

Figure 2
Distribution of Raw Odds Ratio
Therefore, what is typically done with raw odds ratio is transformed to a scale symmetric
about zero by taking the natural logarithm. The log transformation makes the scale symmetric:
the log of 0 is minus infinity, the log of 1 is zero, and the log of infinity is infinity. This
transformation yields the log odds ratio in which a value of one indicates no intervention effect
figure 3 (Petscher & Schatschneider, 2013). Once, the log transformation is done the log OR can
be compared and conclusions concerning the magnitude of the intervention effect can be
analyzed. Graphical displays for meta-analysis performed on ratio scales usually use the log
scales as well. This has the effect of making the confidence intervals appear symmetric, for the
same reason (Higgins & Green, 2011).
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Figure 3
Distribution of Log Odds Ratio
The odds ratio is transformed from raw units to log units to compute the Z-score and
confidence limits. The ln (ORMH) is computed by taking the natural log (ln) of ORMH.

ln ORMH  ln(ORMH )
The MH approach required the following computed frequency values for each study to be
calculated, which will be summed across all studies, and then used to compute the variance of
the summary effect. For each study (i) calculate the following values (the variable name is not
significant):

Ri 

Ai * Di
ni

Si 

B i *Ci
ni

Ei 

( Ai  Di ) Ai * Di
ni2
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Fi 

( Ai  Di ) B i *Ci
ni2

Gi 

( Bi  Ci ) Ai * Di
ni2

Hi 

( Bi  Ci ) B i *Ci
ni2

MH Pooled Variance of the Summary Effect, in log units

Vln ORMH

k
k
k
 k

  Ei
Fi   Gi
Si 


i 1
 0.5  i 1 2  i k1
 i 1 2 
k
 k

 k  
R
*
S
   Ri 

i  i
  Si  

i

1
i

1
 i 1  
  i 1 

MH Pooled Standard Error Estimate

SEln ORMH  Vln ORMH
MH 95 percent Confidence Interval for the Summary Effect, in log units:

LowerLimit  ln(ORMH )  1.96 * SEln ORMH
UpperLimit  ln(ORMH )  1.96 * SEln ORMH
MH Z Value
The calculation of the Z-value and the one-tailed test for the p-value are as follows where Φ
(Z) is the standard normal cumulative distribution.
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Z

ln ORMH
SEln ORMH

p  1  (  Z )
Heterogeneity
In meta-analysis, the usual way of assessing whether a set of single studies is homogeneous
is by means of the Q statistic; however, the Q statistic only informs meta-analysts about the
presence versus the absence of heterogeneity, but it does not report on the extent of such
heterogeneity. The I2 index is used to report the extent of heterogeneity. The principal
advantage of I2 index is that it can be calculated and compared across meta-analyses of different
sizes, of different types of study, and using different types of outcome data (Higgins &
Thompson, 2002).
Q Statistic
The Q statistic is useful in detecting the with-in study variation. The Q statistic has a chisquared distribution with k-1 degrees of freedom where k is the number of studies utilized in the
meta-analysis (Lipsey & Wilson, 2001). The Q statistic is testing the null hypothesis in that the
studies are homogeneous in the combined analysis or H0: Q = 0 implying the studies is
evaluating the same effect versus the alternative hypothesis, HA: Q



0 implying the studies is

not evaluating the same effect in the combined analysis.
The formula for the Q statistic:

Q   wi ( LnORi  LnOR MH )
The Q statistic can produce inaccurate results in extreme situations. When there is only a
few studies the Q statistic can give a false assumption of homogeneity. On the other hand, when
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there are a large number of studies, the Q test has high power to detect even a small amount of
heterogeneity that may be clinically unimportant. When the meta-analysis incorporates only a
few studies, utilizing the random effect model is appropriate when there are concerns about
homogeneity. The random-effects method incorporates an assumption that the different studies
are estimating different, yet related, intervention effects. The random-effects method and the
fixed-effect method will give identical results when there is no heterogeneity among the studies.
I2 Index
The I2 index is also used in detecting heterogeneity between studies which can be interpreted
as the percentage of variability in effect estimates that are due to heterogeneity rather than
chance or sampling error. Between-study heterogeneity is estimated using the I2 statistic;
typically, values greater the 50 percent are considered large, 25 percent to 50 percent modest,
and less than 25 percent low heterogeneity (Higgins & Green, 2011). The formula for the I2
index:

I

2

 Q  df

 Q


 *100%


In meta-analyses that include between 2 to 4 studies such a sample is not usually adequate to
accurately estimate heterogeneity, leading to a false homogeneity assumption (Kontopantelis,
Springate, & Reeves, 2013). These estimates can have large uncertainty, especially in the
presence of few trials, and should be interpreted with caution.
Publication Bias
Publication bias is assessed using a funnel and forest plots. A funnel plot is a scatter plot of
the effect estimates from individual studies against the measure of each study’s precision. A
forest plot is a graphical representation of meta-analysis data.
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In a funnel plot the y axis is the standard error of the effect estimate and the natural log of the
odd ratio is the x axis. The diagonal lines indicate the triangular region within which 95 percent
of studies are expected to lie in the absence of both biases and heterogeneity (Sterne et. al.,
2011). The solid vertical line is the line of no intervention effect. A funnel plot places effect
estimate for larger, more powerful studies are towards the top of the plot and estimates from
smaller, less powerful studies should scatter more widely at the bottom.
In the absence of publication bias we would expect the studies to be distributed
symmetrically about the combined effect size which is observed in the funnel plot. In the
absence of bias and between study heterogeneity, the scatter will be due to sampling variation
alone and the plot will resemble a symmetrical inverted funnel. If no bias is present then the
fixed effect assumption that the true treatment effect is the same in each study is valid.
By contrast, in the presence of bias, we would expect that the bottom of the plot would show
a higher concentration of studies on one side of the mean than the other. This would reflect the
fact that smaller studies (which appear toward the bottom) are more likely to be published if they
have larger than average effects, which makes them more likely to meet the criteria for statistical
significance (Borenstein et al., 2009).
When assessing forest plots one should compare the point estimate for each study to all other
studies included in the meta-analysis, and to the combined point estimate to assess publication
bias. The point estimates should not be scattered across the graph, for example, if one point
estimate favors the control and the other point estimate favors the treatment that could indicate
that publication bias may be present in a meta-analysis. The assessment of a forest plot should
be to evaluate the graph holistically. The graph portion should have the point estimate for each
study that is grouped close together near the summary effect estimate. The point estimates
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should not be scattered across the graph, for example if one point estimate favors the control and
the others point estimates favor of the treatment that is an indication that bias may be present in
the meta-analysis. The 95 percent CI should overlap similar portions and also overlap the
summary effect estimate.
The forest plot provides the summary data entered for each study. In addition, it provides the
weight for each study; the effect measure, method and the model used to perform the metaanalysis; the confidence intervals used; the effect estimate from each study, the overall effect
estimate, and the statistical significance of the analysis. In a forest plot the vertical line which
corresponds to the value one is the line of no intervention effect. If one is included in the 95
percent confidence intervals, it indicates that there is no statistical significant difference between
the treatment and control at five percent significance level. If one is not included in the 95
percent confidence intervals, it indicated that there are statistically significant difference between
the treatment and control at five percent significance level. This is applicable for effect estimates
for the individual study level and for the overall estimate for the meta-analysis.
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Chapter IV: RESULTS
The results of the systematic review resulted in only three eligible trials that met the defined
search parameters. The key elements for the clinical trials are that patients had disease
progression while on or after treatment that included an anthracycline, a taxane, and trastuzumab.
Analysis was conducted using Comprehensive Meta-Analysis software (Version 3.3.070,
Biostat, Englewood, NJ).
The studies randomized patients 1:1 to lapatinib plus capecitabine or capecitabine. The
eligible trials identified 1,131 patients with HER2 positive breast cancer, 576 assigned to
lapatinib plus capecitabine (LC) and 555 assigned to capecitabine (C). The data extracted from
the clinical trials is detailed in table 3.
Table 3
Lapatinib plus Capecitabine versus Capecitabine Data Table
Lapatinib + Capecitabine
Study

Event

Cameron

Capecitabine

16

NonEvent
39

Total

12

85

206

92

71

163

207

8
Geyer
1
Kaufman

Event
1
72
1
26
1
04

NonEvent
29

Total

Study

201

Total
408

67

193

399

57

161
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I used the number of events per arm to calculate odds ratio (OR) and their 95 percent
confidence interval (CI). An event is defined as patient death , the spread of cancer to new
locations within the body, or increased growth of a cancerous lesion. The combined ORs to
calculate pooled point estimates with the corresponding CIs using the Mantel-Haenszel fixed
effect method. I tested heterogeneity using the Q statistic and I2 index. Publication bias is
assessed using funnel and forest plots.
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Mantel-Haenszel Odds Ratio
The summary the odds ratio is shown in Figure 4. Each study is shown by the point estimate
of the odds ratio, lower and upper limits of the 95 percent confidence interval, p-value and forest
plot. The forest plot the square black box indicates the relative weight assigned to each study
and the 95 percent confidence interval is shown by the extending whiskers. The combined odds
ratio estimate and the 95 percent confidence interval by MH fixed effect calculations are shown
by the diamond at the bottom. The diamond is centered at the combined point estimate and the
width of the diamond reflects the 95 percent confidence interval.

Mantel - Haenszel Odds Ratio
Model

Study name

Statistics for each study
MH
odds ratio

Cameron
Geyer
Kaufman
Fixed

0.726
0.757
0.710
0.733

Lower
limit
0.429
0.504
0.454
0.565

Upper
limit
1.228
1.136
1.111
0.952

MH odds ratio and 95% CI
p-Value
0.233
0.179
0.134
0.020
0.5

1
Lapatinib + Capecitabine

2
Capecitabine

Figure 4
Mantel-Haenszel Odds Ratio
The analysis of the odds ratio shows that the Cameron study has a point estimate of 0.726, 95
percent CI of 0.429 to 1.228 and a p value of 0.233. Based on this result the Cameron study does
not show a decrease in tumor progression because the 95 percent confidence interval of the study
overlaps one the line of no intervention effect. So, there is no statistical significance at the study
level.
The analysis of the odds ratio shows that the Geyer has a point estimate of 0.757, 95 percent
CI of 0.504 to 1.136 and a p value of 0.179. Based on this result the Geyer study does not show
32

a decrease in tumor progression because the 95 percent confidence interval of the study overlaps
one the line of no intervention effect. So, there is no statistical significance at the study level.
The analysis of the odds ratio shows that the Kaufman has a point estimate of 0.710, 95
percent CI of 0.454 to 1.111 and a p value of 0.134. Based on this result the Kaufman study does
not show an a decrease in tumor progression because the 95 percent confidence interval of the
study overlaps one the line of no intervention effect. So, there is no statistical significance at the
study level.
The analysis of the odds ratio shows the combined meta-analysis has a point estimate of
0.733, 95 percent CI of .565 to .952 and a p value of 0.020. Based on this result the combined
meta-analysis the 95 percent confidence interval combined effect estimate does not overlap one
the line of no intervention effect. There is statistical significance at the meta-analysis level. The
odds ratio point estimate of 0.733 represents an overall 26.7 percent a decrease in women
experiencing tumor related events in the lapatinib plus capecitabine arm versus the capecitabine
monotherapy. Even though the benefit is moderate it shows that there is statistical support to
pursue new clinical trials utilizing lapatinib plus capecitabine as a new treatment option for
women with metastatic breast cancer.
Heterogeneity
The test for heterogeneity utilizing the Q statistic and I2 index are recorded in the figure 5.

Figure 5
Q statistic and I2 index
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The fixed and random effect models produce the same point estimate, Z-value, and p value
meaning there is no heterogeneity among the studies. The fixed effect model is more
conservative than the random effect model so I am reporting the results for the fized effect
model.
The I2 index is the percentage of variability in effect estimates that are due to heterogeneity
rather than chance or sampling error. The I2 index has a value of 0.000 which suggest that there
is low heterogeneity in this meta-analysis. Since, this meta-analysis includes only three clinical
studies the sample size may not be adequate to accurately estimate heterogeneity resulting in an
incorrect zero of the I2 index. Potentially leading to a false homogeneity assumption and should
be interpreted with caution. In general, meta-analyses which include between two to four studies
are not usually adequate to accurately estimate heterogeneity, leading to a false homogeneity
assumption (Kontopantelis, Springate, & Reeves, 2013). These estimates may have a large
uncertainty due to the lack of published clinical trials available for examination and should be
interpreted with caution.
Publication Bias
Publication bias is assessed with a funnel plot and a forest plot. The table 4 is the natural log
(ln) of the odds ratio for each of the included studies.
Table 4
Natural Log of Mantel-Haenszel Odds Ratio
Study Name

MH Odds Ratio

ln (MH odds ratio)

Cameron

0.726

-0.320

Geyer

0.757

-0.278

Kaufman

0.710

-0.342

Combined

0.733

-0.311
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In a funnel plot the standard error of the effect estimate is the y axis and the natural log of the
odd ratio is the x axis. The vertical line represents the natural log of the combined estimate of
0.733 which has a value of -0.311. Comprehensive Meta-Analysis software uses the term log to
represent the natural log. All the studies are represented by the open circles in figure 6.
Funnel Plot of Standard Error by Log odds ratio
0.0

Standard Error

0.1

0.2

0.3

0.4
-2.0

-1.5

-1.0

-0.5

0.0

0.5

1.0

1.5

2.0

Log odds ratio

Figure 6
Funnel Plot of Standard Error by Log Odds Ratio
Starting from the top of the graph the first circle corresponds to the Geyer study, the second
circle corresponds to the Kaufman study and the final circle corresponds to Cameron study. The
relative weight of each study is indicated by their location on the funnel plot. The Geyer study
has largest relative weight, since it is located at the top of the graph. The Kaufman study has the
second largest relative weight, since it is located between the Geyer and Cameron studies. The
Cameron study has the smallest relative weight comapared to Geyer and Kaufman. All the
studies are close to the fixed estimate and closely grouped together which indicates the metaanalysis is not expressing publication bias. In the absence of publication bias we would expect
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the studies to be distributed symmetrically about the combined effect estimate which is observed
in the above funnel plot.
The second method of detecting publication bias is by a forest plot. The forest plot figure 7
includes the study name, MH odds ratio estimate, the lower and upper limits of the 95 percent
CI, the p value, a line graph of the point estimate with extending whiskers representing 95
percent CI, and the relative weight assigned to each study.

Figure 7
Forest Plot and Relative Weight Analysis

The first assessment of the forest plot is to assess the plot holistically. The graph portion
shows that each study point estimate (vertical line) is either slightly above or below the
combined point estimate. The 95 percent CI cover the same portion of the graph for each study
as well as the summary effect estimate. All the study point estimates favor the treatment
intervention of lapatinib plus capecitabine. Based on the funnel and forest plots this metaanalysis is not representing publication bias.
In assessing the relative weights of studies, a large study provides a good estimate of the
common effect and is assigned a larger weight; a small study offers a less reliable estimate of
that same effect, so it is assigned a smaller weight. The Cameron study point estimate is 0.726
with a relative weight of 24.88 percent; the Kaufman study point estimate is 0.710 with a relative
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weight of 34.49 percent; the Geyer study point estimate in 0.757 with a relative weight of 40.62
percent. Under the fixed effect model these studies are all estimating the same effect with the
Geyer study providing a more precise estimate of the effect. Consequently, the Geyer study is
assigned 40.62 percent of the weight in the combined point estimate with the remaining 59.38
percent divided amongst the remaining studies. Since, the Geyer study is assigned a
disproportionate amount of weight it is evident that the Geyer study is more significant,
statistically, than the Kaufman and Cameron studies. The disproportionate weight given to the
Geyer study has caused the combined point estimate to definitively shift in favor of the Geyer
point estimate.
The study by Geyer has a point estimate of 0.757, a 95 percent CI of 0.504 to 1.136, a p
value of 0.179, and a relative weight of 40.62 percent. Based on the above forest plot the Geyer
study the 95 percent CI includes the value one which indicates there is no treatment difference
between lapatinib and capecitabine versus capecitabine monotherapy. As a result, there is no
statistical significance at the study level. The Geyer study has the smallest variance therefore the
study has more relative weight than Cameron and Kaufman studies.
The study by Kaufman has a point estimate of 0.710, a 95 percent CI of 0.454 to 1.111, a p
value of 0.134, and a relative weight of 34.49 percent. Based on the above forest plot the
Kaufman study shows 95 percent CI includes the value one which indicates there is no treatment
difference between lapatinib and capecitabine versus capecitabine monotherapy. As a result,
there is no statistical significance at the study level. The Kaufman study has a slightly larger
variance when compared to Geyer therefore the study has more relative weight than the Cameron
study.
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The study by Cameron has a point estimate of 0.726, a 95 percent CI of 0.429 to 1.228, a p
value of 0.233, and a relative weight of 24.88 percent. Based on the above forest plot the
Cameron study shows 95 percent CI includes the value one which indicates there is no treatment
difference between lapatinib and capecitabine versus capecitabine monotherapy. As a result,
there is no statistical significance at the study level. The Cameron study has the largest variance
therefore the study has the least relative weight when compared to Geyer and Kaufman.
The combined meta-analysis result has a point estimate of 0.733, a 95 percent CI of .565 to
.952, and a p value of 0.020. Based on the above forest plot the combined fixed point estimate,
the 95 percent confidence interval (indicated by the left and right edges of the diamond) of the
combined point estimate does not overlap value one which indicates there is a statistically
significant treatment difference between lapatinib and capecitabine versus capecitabine
monotherapy at five percent significance level. So, there is statistical significance at the metaanalysis level. New hypotheses can be evaluated in phase II or III clinical trials utilizing
lapatinib plus capecitabine in the treatment of metastatic breast cancer.
Utilizing lapatinib plus capecitabine as first line therapy will provide a more accurate
estimate of the survival benefit to women diagnosed with metastatic breast cancer then provided
in this meta-analysis. The odds of an event occurring in the combination therapy group was
reduced by 26.7 percent when compared to the monotherapy group. There is currently a clinical
trial NCT00496366 Phase II Trial of Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line
Therapy in Patients With HER2/Neu-Overexpressing Advanced or Metastatic Breast Cancer
sponsored by Rutgers, The State University of New Jersey. The clinical study is ongoing and
expected to be concluded in September of 2016 with survival and time to progression data.
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The use of lapatinib plus capecitabine should also be considered for women who are older or
have compromised cardiac function at time of initial diagnosis. Older women are at a 20 percent
increased risk of developing congestive heart failure after finishing chemotherapy. The clinical
trial NCT01262469 Phase II Study Evaluating the Toxicity and Activity of the Combination
Lapatinib + Capecitabine in Elderly Patients Aged 70 and Over with Metastatic Breast Cancer
over Expressing HER2 sponsored by UNICANCER has concluded, but the clinical results of this
trial have not been published. This clinical study will give a more precise cardiac toxicity profile
and survival benefit of lapatinib plus capecitabine in older patients.
The clinical trials mentioned above offer a new option for newly diagnosed HER 2 positive
breast cancer patients. Current research is investigating the role of lapatinib in combination with
other chemotherapy agents and in adjuvant therapy for early breast cancer progression or relapse.
The common benefit for lapatinib plus capecitabine is the convenience of oral administration.
No longer, will women have to take time out of their schedules for their weekly or monthly
chemotherapy infusions thus improving quality of life.
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Chapter V: CONCLUSION
The primary limitation of this meta-analysis is the small number of clinical trials used when
interpreting the results. First, my approach was based on data abstracted from publications and
not individual patient data; thus, results should be viewed as hypothesis generating, and not as
definitive evidence. Second, using short term results from only three randomized trials may be a
source of bias when calculating the combined point estimate. Additional limitations are the
sources of heterogeneity not taken into account due to the limited number of available studies,
such as: clinical differences among the patient populations, patient baseline disease severity or
characteristics, study design, or other sources that are not easily detected.
The goal of chemotherapy or treatment is to maximize quality of life, prolong life, stabilize
the disease, and manage or reduce symptoms. Lapatinib plus capecitabine indicated the event
occurred 26.7 percent less frequently for women treated with combination lapatinib plus
capecitabine in comparison to women treated with capecitabine monotherapy. Although the
decreased odds of tumor advancement is moderate, it is significant when life expectancy is
measured in weeks and not years.
The ultimate cure for breast cancer remains elusive, but there is still hope for a cure with our
advancements in medical science, for instance earlier detection and targeted chemotherapy
drugs. Also our enhanced understanding of genetics, such as testing for breast cancer
susceptibility protein (BRCA) genes and other abnormal genes responsible for cancer
development. The disease is so complex, diverse, and so subtly connected to genetics and
environmental factors, such as hormone therapy after menopause and oral contraceptives, that
finding a cure can often feel impossible. While a cure has not yet been found, public perception
surrounding breast cancer has changed dramatically in the past few decades. Once a disease that
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woman felt ashamed to discuss, breast cancer now has lost much of its stigma. The combined
efforts of Susan G. Komen for the Cure ©, the Breast Health Global Initiative, the U.S. Centers
for Disease Control and Prevention, and advances in medical science has greatly improved
access to treatment and screening. Greater awareness has been brought to this disease and with
increased funding for research and drug development we have seen an increased success rate in
breast cancer treatment.
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APPENDIX
Data Table of the Seven Potentially Eligible Clinical Studies
Author

Lapatinib +
Capecitabine dosing
schedule

Capecitabine dosing
schedule

Included in Metaanalysis

Cameron

Lapatinib 1,250 mg/day of a
21 day cycle

Capecitabine 2,500 mg/m2
on days 1-14 of a 21 day
cycle

Yes, final report for
clinical trial
EGF100151

Capecitabine 2,500 mg/m2
on days 1-14 of a 21 day
cycle

No, interim analysis for
clinical trial
EGF100151

Capecitabine 2,500 mg/m2
on days 1-14 of a 21 day
cycle

No, treatment arm novel
capecitabine dosing
schedule 7 days on 7
days off

Capecitabine 2,500 mg/m2
on days 1-14 of a 21 day
cycle

Yes, final report for
clinical trial
NCT00078572

Capecitabine 2,500 mg/m2
on days 1-14 of a 21 day
cycle

Yes, no clinical trial
identified

Capecitabine 2,500 mg/m2
on days 1-14 of a 21 day
cycle

No, duplicate
publication of clinical
trial NCT00078572

Capecitabine 2,000 mg/m2
days 1-14 of a 21 day cycle
Cameron

Lapatinib 1,250 mg/day of a
21 day cycle
Capecitabine 2,000 mg/m2
days 1-14 of a 21 day cycle

Gajria

Geyer

Lapatinib 1,250 mg/day of a
21 day cycle

Capecitabine 2,000 mg/m2
days 1-7 and 15-21. No
capecitabine day 8-14 of a
21 day cycle
Lapatinib 1,250 mg/day of a
21 day cycle
Capecitabine 2,000 mg/m2
days 1-14 of a 21 day cycle

Kaufman

Lapatinib 1,250 mg/day of a
21 day cycle
Capecitabine 2,000 mg/m2
days 1-14 of a 21 day cycle

Ryan

Lapatinib 1,250 mg/day of a
21 day cycle
Capecitabine 2,000 mg/m2
days 1-14 of a 21 day cycle
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